Astrolabe Diagnostics

Astrolabe Diagnostics has developed a specialized software-as-a-service (SaaS) platform that automates the bioinformatics pipeline for high-dimensional single-cell cytometry data. By leveraging cloud computing and emphasizing automated analysis, the platform significantly reduces the time and expertise required to move from raw data to statistically validated biological insights. The company targets the growing market for scalable, user-friendly computational tools in immunology and oncology research, positioning itself as a force multiplier for research labs and diagnostic developers. As a private, likely venture-backed firm, its success hinges on platform adoption, integration into research workflows, and expansion of its analytical capabilities.

Cloud-based SaaS platform for automated, end-to-end bioinformatics analysis of high-dimensional single-cell cytometry data. Leverages AWS for scalability, combines machine learning with literature-based analytics, and automates clustering, statistical comparison, and visualization to deliver biological insights in hours.

Astrolabe competes in the single-cell bioinformatics space against traditional flow cytometry software (FlowJo, FCS Express), acquired platforms (Cytobank by Beckman Coulter), and a wide array of powerful, free open-source tools and packages (e.g., Seurat, CyTOFkit). Its differentiation lies in its fully automated, cloud-native, end-to-end service model emphasizing speed and accessibility for non-experts.